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Abstract
Introduction The identification and follow-up of ultra-short Barrett’s esophagus (BE) is controversial. BE surveillance guide-
lines emphasize mainly on long-segment BE. However, in practice a substantial proportion of esophageal adenocarcinoma 
(EAC) are found close to the gastro-esophageal junction (GEJ). Our study aims to chart the length of BE when low-grade 
dysplasia (LGD), high-grade dysplasia (HGD) and EAC arise in BE.
Methods Endoscopic findings from all cases with a diagnosis of LGD and HGD in BE between June 2014 and June 2019, 
and 100 consecutive cases of EAC diagnosed between June 2018 and August 2019, were reviewed. Additionally, 438 con-
secutive gastroscopies were reviewed to identify 100 cases of non-dysplastic BE.
Results 99 cases of LGD and 61 cases of HGD were reviewed. LGD and HGD when diagnosed, was located in BE ≤ 1 cm 
in 20% and 18% cases, respectively. LGD and HGD when diagnosed, was located in BE ≤ 3 cm in 48.5% and 40.9% cases, 
respectively. LGD and HGD when diagnosed in BE ≤ 3 cm was found at index endoscopy in 67% and 42% cases, respectively. 
Of the 100 cases of EAC, only 23 had concurrent visible BE, with BE higher than the level of EAC in seven. EAC when 
found, had its proximal extent ≤ 1 cm from GEJ in 22% and ≤ 3 cm from GEJ in 40% cases. Of the 100 non-dysplastic BE, 
53% were ≤ 1 cm and 78% were ≤ 3 cm long.
Conclusion Almost 20% of all dysplasia in BE occurs in BE < 1 cm. Over 40% occurs in BE < 3 cm. Similarly, 20% of EAC 
occurs within 1 cm of GEJ and 40% occur within 3 cm. A majority of dysplasia diagnosed within 3 cm of the GEJ is found 
on index endoscopy. We propose that all lengths of columnar lined epithelium above the GEJ are recognized as BE and 
subjected to a thorough biopsy protocol.
The prevalence and incidence of esophageal adenocarci-
noma (EAC) is increasing in the western world [1, 2]. Risk 
factors for EAC are Barrett’s esophagus (BE) and longstand-
ing symptomatic gastro-esophageal reflux disease (GERD) 
[1, 3]. It is accepted that BE progression follows the clas-
sic cellular sequence of BE to low-grade dysplasia (LGD) 
to high-grade dysplasia (HGD) to EAC [4–6]. As a result, 
it is established practice to offer surveillance once BE is 
diagnosed.
Several studies have shown that BE progression rate is 
generally very low but is higher as the length of BE increases 
[7–9]. Short-segment BE (SSBE) defined as BE ≤ 3 cm is 
considered to have lower risk of progression as against long-
segment BE (LSBE) defined as BE > 3 cm. [4, 10, 11]. It is 
also accepted that BE diagnosed EAC has better prognosis 
and survival advantage [12–14].
This has led to authoritative guidelines both by the 
American College of Gastroenterologists (ACG) and Brit-
ish Society of Gastroenterologists (BSG) recommending BE 
surveillance protocols [15, 16]. Guidelines summarized in 
Table 1 do focus on more regular LSBE surveillance with 
much infrequent SSBE surveillance. Ultra-short BE (USBE) 
defined as BE ≤ 1 cm is not even considered for diagnosis 
or surveillance.
Despite acknowledging that BE is a risk factor for devel-
opment of EAC and having surveillance programs for 
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several decades, the current BE surveillance detected EAC 
rate remains very low with only 3–8% of diagnosed EAC 
have previously known BE [14, 17, 18]. It takes around 200 
patients years of BE surveillance to diagnose one EAC, with 
most patients with BE dying of other causes [19–21]. The 
financial burden of BE is also high for health care systems 
and individuals [22, 23]. Furthermore, the survival advan-
tage for BE surveillance diagnosed EAC is often questioned. 
In their case–control study, Corley et al. found that BE sur-
veillance did not lead to improved EAC outcomes [24]. Bet-
ter outcomes in EAC diagnosed by BE surveillance could 
also be due to lead time and length time bias [25]. As a 
result, unless the EAC pick-up rate from BE surveillance is 
improved radically, BE surveillance cannot be considered 
very effective.
We postulate that the focus on LSBE surveillance as 
against SSBE and disregarding USBE from BE diagnosis 
may be partly responsible for poor EAC pick-up rate on BE 
surveillance. If longer length of BE is an important pre-
dictor of progression then we should either find EAC more 
frequently higher up and away from the gastro-oesophageal 
junction (GEJ) within a LSBE or alternatively simply a long 
EAC involving the entire LSBE; or a focal EAC near the 
GEJ with LSBE above it. However, in practice, a substantial 
proportion of EAC are found close to the GEJ without co-
existent long-segment BE. Our study aims to chart the length 
of BE when LGD, HGD and EAC arise in BE and to identify 
the topographic location of EAC and non-dysplastic BE.
Methods
Study design
This was a retrospective analysis of a contemporaneously 
maintained database at a regional upper gastro-intestinal 
cancer center in the United Kingdom. Patients with a diag-
nosis of LGD or HGD in BE and EAC were included. Data 
collection included patient demographics (such as gender 
and age at first endoscopy diagnosis), histology results, and 
confirmation of histological diagnosis by 2 histopathologists 
and presence or absence of intestinal metaplasia. Descrip-
tion of BE was done endoscopically using the Prague clas-
sification system that measures the circumferential (C) and 
maximal (M) extents of BE lengths introduced by the Inter-
national Working Group for the Classification of Esophagitis 
(IWGCO) in 2004 [26].
In addition, 438 consecutive gastroscopies by a single 
endoscopist who accurately recorded columnar lined epi-
thelium above the GEJ were analyzed to identify 100 cases 
of non-dysplastic BE.
Three groups of data were analyzed:
Group 1 (Dysplastic BE) All cases with a histological diag-
nosis of LGD and HGD in BE between June 2014 and June 
2019. For these patients, their demographic data and endo-
scopic features were reviewed.
Group 2 (EAC) 100 consecutive cases of EAC diagnosed 
between June 2018 and August 2019. For these patients, 
their demographic data and specific endoscopic features 
including exact site of tumor, upper extent of cancer from 
the GEJ and any associated BE above the level of EAC were 
reviewed.
Group 3 (Non-dysplastic BE) 100 consecutive cases of 
non-dysplastic BE between June 2018 and August 2019. 
For these patients, their demographic data and endoscopic 
features were reviewed.
Sample size
Dysplasia in BE is not very common. To maximize the num-
ber of cases in the dysplastic BE group, we included all 
consecutive cases recorded as LGD or HGD in BE from 
our histopathology database over the preceding five years at 
the start of our study. After applying the exclusion criteria, 
discussed below, a study sample of 160 cases on dysplastic 
BE cases were analyzed. A sample size of 100 consecutive 
EAC and 100 non-dysplastic BE were deemed adequate to 
represent the more common conditions of EAC and BE.
Definitions
For the purposes of this study, BE was defined, according 
to the BSG guidance, as an esophagus in which any por-
tion of the normal distal squamous epithelial lining had 
been replaced by metaplastic columnar epithelium, which 
was clearly visible endoscopically above the GEJ and con-
firmed histopathologically from esophageal biopsies [16]. 
A histological diagnosis was performed as per minimum 
reporting standards in the BSG guideline. Therefore the 
Table 1  Current ASG and BSG guidelines on Barrett’s surveillance
ASG guideline BSG guideline
BE length Surveillance interval BE length Surveillance interval
 < 1 cm No further surveil-
lance
 < 1 cm No further surveil-
lance










 > 3 cm 2–3 years
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presence of intestinal mucosa was not necessary for BE 
in our study. LGD or HGD was identified by two histo-
pathologists or confirmed at Multi Disciplinary Team 
(MDT) review where a two histopathology review was not 
achieved. Other definitions are as follows:
USBE was defined as up to 1 cm of columnar lined 
mucosa above the gastric mucosal folds (see Fig. 1).
SSBE is defined as ≥ 1 cm to < 3 cm Barrett’s esophagus 
(see Fig. 2).
LSBE is defined as ≥ 3 cm Barrett’s esophagus (see 
Fig. 3).
Exclusion criteria
For Group 1 (Dysplastic BE) Any patient who had squa-
mous dysplasia, indeterminate dysplasia or those who 
had previous history of endoscopic ablative or resectional 
therapy were excluded. Data for patients with a diagno-
sis of dysplasia more than once in the study period were 
recorded from the initial diagnostic episode.
For Group 2 (EAC) Patients with Siewert type III GEJ 
tumors were excluded.
For Group 3 (non-dysplastic BE) Patients with irregu-
lar z-line (squamo-columnar junction) were excluded (see 
Fig. 4).
Ethics and consent
Data analyzed in this study was used from a contempo-
raneously maintained database from Histopathology and 
Endoscopy units at our institute. Data review was approved 
by local Clinical Effectiveness Unit (CEU project regis-
tration number: 9341). No patient identifying information 
was recorded and patient consent was not required for data 
review as per CEU guidelines.
Fig. 1  Barrett’s esophagus was classed as USBE (1) when the 
squamo-columnar junction was < 1  cm above the gastro-esophageal 
junction or the level of the highest gastric mucosal fold (blue dot-
ted circle). Incidentally, in this case HGD was found in the nodule 
(arrows)
Fig. 2  Barrett’s esophagus was classed as SSBE (1) when the 
squamo-columnar junction was ≥ 1  cm to < 3  cm above the gastro-
esophageal junction or the level of the highest gastric mucosal fold 
(blue dotted circle). Incidentally, in this case LGD was found with no 
visible lesion
Fig. 3  Barrett’s esophagus was classed as LSBE when the squamo-
columnar junction was > 3 cm above the gastro-esophageal junction




This group comprised 160 patients. 99 cases of LGD and 
61 cases of HGD were identified. Median age was 70. 126 
were male (79%). 118 (74%) of cases were reviewed by 
2 pathologists. All cases having a diagnosis of LGD for 
the second time or after initial diagnosis of HGD were 
reviewed in a MDT meeting. Median circumferential BE 
was 2 cm and median maximal extension was 4 cm. Back-
ground intestinal metaplasia was confirmed histologically 
in 142 (89%) of these cases.
LGD and HGD when diagnosed, was located in BE ≤ 1 cm 
in 20 cases (20%) and 11 cases (18%), respectively. LGD 
and HGD when diagnosed, was located in BE ≤ 3 cm in 48 
cases (48.5%) and 25 (40.9%) cases, respectively. In 30 cases 
(19%) either LGD or HGD was present < 1 cm from the GEJ. 
Table 2 shows a detailed comparison of results between the 
LGD and HGD groups.
LGD and HGD when diagnosed in BE ≤ 3 cm, was found 
at index endoscopy in 67% and 42% cases, respectively. 
The rest of the cases were diagnosed while on BE surveil-
lance. Of all the cases of LGD in BE ≤ 3 cm found at index 
endoscopy, 65% had no visible lesions in the BE segment, 
whereas the rest had ulcer/inflammation (19%) or nodules 
(16%). In these cases of LGD (in BE ≤ 3 cm), the common-
est indications for index endoscopy were reflux symptoms 
(39%), dysphagia (32%) and anemia or gastro-intestinal (GI) 
bleeding (19%). Of all cases of HGD in BE ≤ 3 cm found at 
index endoscopy, 50% had no visible lesions in the BE seg-
ment, whereas nodules were seen in 40% and ulcer in 10%. 
In these cases of HGD (in BE ≤ 3 cm), the indications for 
index endoscopy were dysphagia (50%), reflux symptoms 
(30%) and anemia (20%).
The proportion of LGD and HGD diagnosed at index 
endoscopy was even higher in cases when BE was ≤ 1 cm, 
with 70% and 67% of cases being diagnosed at index endos-
copy, respectively. In these cases of LGD and HGD diag-
nosed at index endoscopy, when BE was ≤ 1 cm long, 64% 
and 73%, respectively, had no visible lesions in the BE 
segment.
Group 2
Group 2 comprised 100 consecutive cases of EA diagnosed 
between June 2018 and August 2019. In this category, 78 
(78%) were males. Median age at diagnosis was 70 years. 
Only 23 cases (23%) had concurrent visible BE. If no BE 
Fig. 4  Squamo-columnar junction was defined as ‘irregular z-line’ 
(bold arrow) rather than Barrett’s esophagus, when was present with 
inflammation (1) and mostly within the level (blue dotted circle) of 
the highest gastric mucosal fold (2)
Table 2  Demographics, 
pathology and position of LGD 
and HGD
LGD HGD
Number of cases 99 61
Gender Male = 79 (79.8%) Male = 47 (77%)
Female = 20 (20.2%) Female = 14 (23%)
Median age 69 70
2 pathologist reporting 67 (67.7%) 51 (83.6%)
Median circumferential BE 2 cm 2 cm
Background intestinal metaplasia 88 (88.8%) 54 (88.5%)
Median maximal BE extensions 4 cm 4 cm
Length of BE from GEJ
 < 1 cm 20 (20.2%) 11 (18%)
 < 3 cm (includes < 1 cm) 48 (48.5%) 25 (40.9%)
 > 3 cm 51 (51.5%) 36 (59%)
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was visible, it was acknowledged that the EAC had com-
pletely overgrown into the existing Barrett’s epithelium.
In 22 (22%) cases EAC was reported to have a proxi-
mal extent ≤ 1 cm from GEJ. 18 cases (18%) were detected 
between 1 and 3 cm from the GEJ, and the majority of cases 
(60%) were detected > 3 cm above GEJ.
Of the 100 cases of EAC, BE was visible above the level 
of tumor in 7 cases. When BE was visible concurrently with 
EAC: it was recorded ≤ 1 cm from the GEJ in 6 cases; ≤ 3 cm 
from the GEJ in 14 cases; and > 3 cm from the GEJ in 9 
cases.
Group 3
This group consisted of 100 cases of non-dysplastic BE 
between June 2018 and August 2019. 71 patients were male. 
Median age was 68 years. In 53 cases (53%) BE was detected 
within 1 cm and 78 cases (78%) were ≤ 3 cm of the GEJ. 22 
cases (22%) were reported as > 3 cm (LSBE).
Discussion
Our study focussed on measuring the length of BE when 
LGD, HGD and EAC were diagnosed. Our results show 
that a substantial proportion of the diagnosed LGD and 
HGD are located in short-segment BE, with around one-
fifth in ≤ 1 cm BE. Similarly around one-fifth of EAC occur 
within 1 cm of the GEJ without adjacent long-segment BE. 
When accurately identified, by reviewing 438 consecutive 
gastroscopies, over 50% of BE is ≤ 1 cm of the GEJ. This 
would lead us to postulate that current system of Barrett’s 
surveillance will not pick-up a proportion of EAC and dys-
plasia as columnar lined epithelium ≤ 1 cm is disregarded 
from diagnosis and surveillance.
Though LSBE is considered as a risk factor for progres-
sion, multiple studies show SSBE risk is statistically similar 
to LSBE [7, 10, 27]. ACG and BSG accept that BE surveil-
lance guidelines are based on poor quality evidence [16, 23]. 
If most studies do not include USBE in the diagnosis and 
surveillance of BE, the established literature would invari-
ably show a bias towards LSBE which is easy to identify 
and study. LSBE and SSBE are arbitrarily defined by a 
length of 3 cm from GEJ. It is well recognized that there 
is a substantial inter-observer variation in the measurement 
of BE length [26]. Alvarez Herrero et al. have shown that 
BE length may vary by 1–2 cm between two endoscopic 
records [28]. Similar observer variability in recording BE 
length has been shown previously [29, 30]. This means that 
there is the potential for a 2 cm BE to be called USBE and 
ignored from surveillance, and a 2–3 cm BE called LSBE, 
falsely increasing the perceived risk from LSBE. We believe 
that stratifying BE risk based on length < or > than 3 cm 
is arbitrary, prone to observer error and clearly not work-
ing. Furthermore, the established system for biopsy in BE, 
requires 4-quadrant biopsies to be taken at every 1–2 cm 
length. If observer error is recognized in establishing the 
length of BE, it would adversely affect the number of biop-
sies taken in shorter lengths of BE.
Various studies have reported and acknowledged the dys-
plasia risk associated with SSBE and USBE [31–33]. Their 
results demonstrate a dysplasia risk of 8 to 12% in patients 
with SSBE. Pohl et al. in their elaborate study in the German 
population, demonstrated that patients diagnosed with early 
(T1) EAC had SSBE in 24% cases and USBE in 20% (over-
all BE ≤ 3 cm in 44% cases) [34]. Unfortunately, such studies 
haven’t impacted in the BE surveillance guidelines as the 
overall prevalence of SSBE and USBE in general population 
is quite high making surveillance financially unviable for 
SSBE and USBE. As such the prevalence of BE in asymp-
tomatic male veterans older than 50 years of age is as high as 
25% with 70% of them ≤ 3 cm long [35]. This is not dissimi-
lar to our study where 23% of 438 consecutive endoscopies 
had BE with 78% being ≤ 3 cm long. This means that while 
it is possible to admit the dysplasia and EAC risk of USBE 
and SSBE, it does not bode well for a surveillance program 
as it will need thousands of endoscopies to diagnose one 
EAC. Looking at the population prevalence of BE, Pohl 
et al. concluded that over 3000 patients with SSBE and over 
12,000 patients with USBE would need endoscopic assess-
ment to diagnose one EAC in each group [34]. Though Pohl 
and colleagues only looked at T1 EAC, we do not expect the 
numbers to reduce drastically if more advanced cancers were 
also included in their study.
Based on current literature discussed above, we must 
recognize that the measurement of BE length may be inac-
curate; SSBE and USBE both have a risk of progressing 
to dysplasia; and surveillance of all cases of BE is logisti-
cally impossible. A different strategy is necessary to identify 
patients likely to progress from BE to EAC.
In our study, a vast majority of LGD and HGD, particu-
larly when BE was ≤ 3 cm long, were diagnosed at index 
endoscopy rather than on surveillance. On sub-analysis of 
the USBE group, the proportion of LGD and HGD diag-
nosed on index endoscopy increased further to 70% and 
67% cases, respectively. Of patients diagnosed with LGD 
and HGD on index endoscopy, when BE was ≤ 1 cm long, 
64% and 73%, respectively, had no visible lesions in the BE 
segment. This data emphasizes the need for more focussed 
biopsies of USBE segment when seen rather than disregard-
ing it from the diagnosis of BE. Similar findings were noted 
by two other prospective cohort studies which reported a 
dysplasia rate at index endoscopy of over 8% for patients 
with a new diagnosis of BE ≤ 3 cm [32, 33].
Our results have demonstrated that a substantial pro-
portion of dysplasia and EAC occur within USBE and 
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SSBE. This highlights the need for recognizing all lengths 
of columnar lined mucosa as BE when seen at endoscopy. 
Once BE is identified multiple accurate directed biopsies 
should be taken to exclude baseline dysplasia at index endos-
copy. We hypothesize that BE surveillance detects a very 
small proportion of EAC due to the lead time bias with only 
the slow growing tumors being picked on surveillance. It 
takes several years or decades to develop a truly long LSBE. 
Inherently, such slow growing LSBE is stable and hence 
dysplasia or EAC occurring in it is more likely to be picked 
up on surveillance. In contrast, the majority of EAC not 
picked on surveillance, perhaps occurs in unstable USBE 
and SSBE, which converts into EAC rapidly without ever 
having a chance to develop into true LSBE. We propose that 
every BE, irrespective of its length, be thoroughly biopsied 
at every endoscopic opportunity, whether or not they are on 
surveillance.
Our study was a retrospective observational study with a 
starting point of dysplasia in BE. This allowed us to review 
a large number of LGD and HGD cases for their endoscopic 
features. To assess true dysplasia risk, one would ideally 
require a large prospective cohort study looking at various 
lengths of BE on a longitudinal follow-up. While this was 
outside the aim and scope of our research, we have managed 
to demonstrate that 46% of the diagnosed dysplasia (LGD 
and HGD) occurs within 3 cm from the GEJ. A prospective 
longitudinal study could only increase that proportion due 
to even better pick-up rate.
Conclusion
Almost 20% of all dysplasia in BE and EAC occur within 
a centimeter of the GEJ. Over 40% occur within 3 cm from 
the GEJ. A majority of dysplasia diagnosed within 3 cm of 
the GEJ is found on index endoscopy. We propose that all 
lengths of columnar lined epithelium above the GEJ are rec-
ognized as BE and subjected to a thorough biopsy protocol.
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